A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Link
http://link.springer.com/content/pdf/10.1007/s10157-014-0989-7.pdf
Reference10 articles.
1. Kansui Y, Ohtsubo T, Goto K, et al. Association of serum uric acid with blood pressure in Japanese men: cross-sectional study in work-site group. Circ J. 2011;75:2827–32.
2. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.
3. Toda A, Ishizaka Y, Tani M, et al. Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. Nephron Clin Pract. 2014;15(126):33–8.
4. Becker MA, Schumachar HR, Wortmann RL, et al. Febuxostat compared allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.
5. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopirinol is common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A possible covalent xanthine oxidase inhibitor TS10: Inhibition mechanism, metabolites identification and PDPK assessment;Bioorganic Chemistry;2022-11
2. The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients;Annals of Palliative Medicine;2022-07
3. Efficacy and tolerability of febuxostat in gout patients on dialysis;Internal Medicine Journal;2021-03
4. Development and validation for the quantitative determination of xanthine oxidoreductase inhibitor topiroxostat by LC-MS/MS and its clinico-pharmacokinetic study;Journal of Pharmaceutical and Biomedical Analysis;2020-09
5. Efficacy and safety of urate‐lowering treatments in patients with hyperuricemia: A comprehensive network meta‐analysis of randomized controlled trials;Journal of Clinical Pharmacy and Therapeutics;2020-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3